Livanova (LIVN) Stock News

LivaNova (LIVN) has announced promising 12-month data from its OSPREY clinical trial for the aura6000™ System, a device treating moderate to severe obstructive sleep apnea (OSA). The study showed a 65% responder rate after 12 months, with significant improvements in key metrics: 68% reduction in both apnea-hypopnea index (AHI) and oxygen desaturation index (ODI). The trial demonstrated rapid onset and sustained improvement, with 25% of patients responding on day one and 50% by month three. The aura6000 System uses proximal hypoglossal nerve stimulation with six electrodes, offering customized treatment. Notably, OSPREY included patients with higher OSA severity, higher BMI, and complete concentric collapse risk compared to similar trials. The company has completed its FDA premarket approval submission, with no serious adverse device-related or procedure-related events reported during the study.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, has scheduled its first-quarter 2025 earnings conference call for Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The company will release its Q1 2025 financial results before the call.

Investors can access the audiocast through www.livanova.com/events, with recommended login 10 minutes before the start. For telephone access, U.S. participants should dial +1 833 470 1428, while international callers can use +1 929 526 1599, with access code 047836. A replay will remain available on the company website for 90 days after the call.

LivaNova PLC (Nasdaq: LIVN) reported strong financial results for Q4 and full-year 2024, with full-year revenue reaching $1.25 billion, an 8.7% increase on a reported basis. The company achieved Q4 revenue of $321.8 million, up 3.8% reported and 6.8% organic compared to the prior year.

Full-year 2024 U.S. GAAP diluted EPS was $1.16, while adjusted diluted EPS reached $3.38. The company generated $183 million in operating cash flow and $162.9 million in adjusted free cash flow.

For 2025, LivaNova expects revenue growth of 5-6% on a constant-currency basis and 6-7% on an organic basis, with adjusted diluted EPS projected between $3.65-$3.75.

The company announced positive clinical milestones, including the OSPREY study for sleep apnea meeting its endpoints and publication of VNS Therapy data for treatment-resistant depression showing clinically meaningful therapeutic effects.

LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, has announced that CEO Vladimir Makatsaria will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation is scheduled for Tuesday, March 11, at 2:00 p.m. Eastern Time.

The event will be accessible via webcast through www.livanova.com/events, with registration required for all interested parties. Attendees are advised to log on approximately 10 minutes before the presentation to ensure proper setup. A replay of the presentation will be available on the LivaNova website within 24 hours and will remain accessible for 90 days following the event.

LivaNova PLC (LIVN) has announced it will release its fourth-quarter and full-year 2024 financial results on Tuesday, February 25, 2025. The company will host a conference call to discuss the results at 1 p.m. London time (8 a.m. Eastern Time) on the same day.

Investors and interested parties can access the audiocast through the company's website at www.livanova.com/events, with recommended login 10 minutes before the start. For telephone access, participants can dial +1 833 470 1428 from the U.S. or +1 929 526 1599 from outside the U.S., using access code 982570. A replay will be available on LivaNova's website for 90 days after the call.

LivaNova (Nasdaq: LIVN) announced publication of two pivotal articles in Brain Stimulation journal regarding the RECOVER clinical study of their VNS Therapy System for treatment-resistant unipolar depression. The study involved 493 adults who had failed over 13 antidepressant treatments on average. While not meeting its primary endpoint, the study showed statistically significant benefits in select secondary endpoints. Active VNS Therapy demonstrated meaningful improvements in quality of life and daily function compared to sham treatment. The study revealed significant benefits in Clinical Global Impression-Improvement (CGI-I) (P=0.004) and Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR) (P=0.049). Three additional manuscripts are planned to report further outcomes.

LivaNova PLC (LIVN) has announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting from December 6-10 in Los Angeles. The company will present multiple scientific posters featuring research on drug-resistant epilepsy treatments, including interim data from their CORE-VNS study.

The presentations will showcase research on VNS Therapy™ applications, including outcomes in children, genetic epilepsy patients, and Lennox-Gastaut Syndrome. Key topics include dosing and titration practices, long-term therapy outcomes, and healthcare services cost comparisons for Medicaid enrollees.

Poster presentations are scheduled for December 7-8, with author presentations from 12:00-2:00 PM PST. Additional displays will be available at the LivaNova Scientific Exhibit on December 9 from 8:00-11:00 AM PST.

LivaNova PLC (Nasdaq: LIVN) has announced its participation in three major healthcare conferences in New York. CEO Vladimir Makatsaria will present business updates through fireside chats at the Stifel Healthcare Conference (November 19, 11:30 AM ET), Wolfe Research Healthcare Conference (November 20, 1:20 PM ET), and Piper Sandler Healthcare Conference (December 3, 10:00 AM ET). All sessions will be livestreamed and available for replay on the company's website.

LivaNova announced successful results from its OSPREY randomized controlled trial for the aura6000 System, an implantable device treating moderate to severe obstructive sleep apnea. The study met its primary safety and efficacy endpoints with statistically significant responder rates between treatment and sham arms. Key secondary endpoints showed impressive results at six months: 66.2% reduction in median apnea-hypopnea index (from 34.3 to 11.6) and 63.3% reduction in oxygen desaturation index (from 34.9 to 12.8). No serious adverse device or procedure-related events were reported. LivaNova plans to submit the data to FDA for premarket approval, with 12-month data expected in first half of 2025.